Fig. 3

The combined use of uric acid and sodium ascorbate increases the tolerance of C. elegans to a mitochondrial inhibitor. A NaN₃ (500 µM) and uric acid (UA, 0, 2 mM) or sodium ascorbate (Vit. C, 0, 4 mM) were supplemented to wild-type (N2) animals at the L4 stage, and the survival time was measured. Log-rank P value: Control vs UA 2 mM < 0.0001. Log-rank P value: Control vs Vit. C 4 mM < 0.0001. Number of trials: Control, 8 times; UA 2 mM, 3 times; Vit. C 4 mM, 3 times. Total number of Control, UA 2 mM, and Vit. C 4 mM-treated animals: 200, 55, and 58, respectively. B NaN₃ (500 µM) and uric acid (0, 2 mM) or sodium ascorbate (0, 4 mM) were supplemented with the xdh-1 mutant (tm9911) animals at the L4 stage, and the survival time was measured. Log-rank P value: Control vs UA 2 mM < 0.0001. Log-rank P value: Control vs Vit. C 4 mM = 0.0204. Number of trials: Control, 10 times; UA 2 mM, 3 times; Vit. C 4 mM, 3 times. Total number of Control, UA 2 mM, and Vit. C 4 mM-treated animals: 225, 71, and 55, respectively. C NaN₃ (500 µM), FBX (0, 20 µg/ml), and sodium ascorbate (0, 4 mM) were administered to wild-type (N2) animals in the L4 stage, and the survival time was measured. Log-rank P value: FBX 0 µg/ml vs. FBX 20 µg/ml, Vit C 4 mM < 0.0001. Log-rank P value: FBX 20 µg/ml vs. FBX 20 µg/ml, Vit C 4 mM < 0.0001. Number of trials: Control, 8 times; UA 2 mM, 3 times; FBX 20 µg/ml + Vit. C 4 mM, 3 times. Total number of FBX 0 µg/ml, FBX 20 µg/ml, and FBX 20 µg/ml + Vit. C 4 mM-treated animals: 200, 106, and 59, respectively